Fennec Pharmaceuticals (TSE:FRX) Stock Rating Upgraded by Stephens

Fennec Pharmaceuticals (TSE:FRX) was upgraded by analysts at Stephens to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Fennec Pharmaceuticals Stock Performance

TSE FRX opened at C$5.69 on Monday. The firm has a 50-day moving average price of C$6.44 and a two-hundred day moving average price of C$8.08. Fennec Pharmaceuticals has a 12-month low of C$5.65 and a 12-month high of C$15.43. The company has a market capitalization of C$155.68 million, a P/E ratio of 56.90 and a beta of 0.25. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.